What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices.

Donald A. Richards,Maen Hussein,Steven L. McCune,Brian Ulrich,Bijoy PanKaj Telivala,Marc Monte,Mark D. Danese,Michelle Gleeson,Deborah P. Lubeck,Jenine Sanzari,John R. Penrod,Y. Yuan,Pranav Abraham,Beata Korytowsky,Lee S. Schwartzberg

What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices.

2018

Donald A. Richards
Maen Hussein
Steven L. McCune
Brian Ulrich
Bijoy PanKaj Telivala
Marc Monte
Mark D. Danese
Michelle Gleeson
Deborah P. Lubeck
Jenine Sanzari
John R. Penrod
Y. Yuan
Pranav Abraham
Beata Korytowsky
Lee S. Schwartzberg

e20567Background: Limited 2L therapy options and no established 3L standard of care make treating relapsed ED-SCLC challenging. This study explores current treatment and outcomes in patients receiv...

Keywords:

Prospective cohort study
Cell
Extensive Disease
Physical therapy
Oncology
Discontinuation
Lung cancer
Internal medicine
Medicine
standard of care
Intensive care medicine
in patient
non small cell
third line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations